Another mouse model of bone disease, osteogenesis imperfecta (OI), showed 2.5-fold increased SLC13A5 expression levels in bone and abnormal mineralization [45] and may provide another hint for beneficial effects of SLC13A5 inhibition on bone health. The gene discussed is SLC13A5; the disease is osteogenesis imperfecta.